MX2016001193A - Medicamento que comprende anticuerpo anti-fosfolipasa d4. - Google Patents
Medicamento que comprende anticuerpo anti-fosfolipasa d4.Info
- Publication number
- MX2016001193A MX2016001193A MX2016001193A MX2016001193A MX2016001193A MX 2016001193 A MX2016001193 A MX 2016001193A MX 2016001193 A MX2016001193 A MX 2016001193A MX 2016001193 A MX2016001193 A MX 2016001193A MX 2016001193 A MX2016001193 A MX 2016001193A
- Authority
- MX
- Mexico
- Prior art keywords
- phospholipase
- present application
- product including
- medicinal product
- including anti
- Prior art date
Links
- 229940126601 medicinal product Drugs 0.000 title 1
- 102100036183 5'-3' exonuclease PLD4 Human genes 0.000 abstract 4
- 101710142129 5'-3' exonuclease PLD4 Proteins 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente solicitud proporciona los medicamentos que comprenden los anticuerpos que se unen a la fosfolipasa D4 (PLD4) así como también un método que utiliza los medicamentos para detectar y suprimir células B activadas. La presente solicitud se dirige además a la terapia de enfermedades autoinmunes y alergosis, que resulta de una función de represión activa. Con el propósito de resolver esos problemas, la presente solicitud proporciona ese anticuerpo monoclonal que se une al dominio extracelular de la proteína de fosfolipasa D4 (PLD4), o un fragmento que contiene una región de unión a antígenos del mismo como un ingrediente activo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013158258 | 2013-07-30 | ||
| PCT/JP2014/070661 WO2015016386A1 (en) | 2013-07-30 | 2014-07-30 | Medicament comprising anti-phospholipase d4 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016001193A true MX2016001193A (es) | 2016-05-26 |
| MX381725B MX381725B (es) | 2025-03-13 |
Family
ID=51493000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001193A MX381725B (es) | 2013-07-30 | 2014-07-30 | Medicamento que comprende anticuerpo anti-fosfolipasa d4. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20160168266A1 (es) |
| EP (1) | EP3027656B1 (es) |
| JP (3) | JP6431523B2 (es) |
| KR (1) | KR102367760B1 (es) |
| CN (1) | CN105745226B (es) |
| AU (1) | AU2014297217B2 (es) |
| BR (1) | BR112016002001B1 (es) |
| CA (1) | CA2919736C (es) |
| DK (1) | DK3027656T3 (es) |
| ES (1) | ES2736324T3 (es) |
| HU (1) | HUE044469T2 (es) |
| MX (1) | MX381725B (es) |
| PL (1) | PL3027656T3 (es) |
| RU (1) | RU2709741C2 (es) |
| SG (2) | SG10201800592SA (es) |
| TR (1) | TR201910330T4 (es) |
| WO (1) | WO2015016386A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| DK2809683T3 (en) * | 2012-01-31 | 2018-12-10 | Sbi Biotech Co Ltd | ANTI-phospholipase D 4 ANTIBODY |
| SG10201800592SA (en) * | 2013-07-30 | 2018-03-28 | Sbi Biotech Co Ltd | Medicament comprising anti-phospholipase d4 antibody |
| BR112019000544A2 (pt) | 2016-07-15 | 2019-04-24 | Takeda Pharmaceutical Company Limited | métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática |
| AU2019208102B2 (en) | 2018-01-12 | 2025-10-09 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-CD38 antibodies |
| JP7140367B2 (ja) * | 2018-05-31 | 2022-09-21 | 国立大学法人 東京大学 | ヒト由来サンプルにおける可溶型ｔｌｒ７の分析 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2091684T3 (es) * | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| WO2000011015A1 (en) * | 1998-08-24 | 2000-03-02 | Alphagene, Inc. | Secreted proteins and polynucleotides encoding them |
| EP1392855A4 (en) * | 2000-12-07 | 2005-05-25 | Millennium Pharm Inc | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF VIRAL DISEASES VIA GENE 55092 |
| JP2013052781A (ja) | 2011-09-05 | 2013-03-21 | Tokai Rika Co Ltd | 車両用ミラー装置 |
| DK2809683T3 (en) * | 2012-01-31 | 2018-12-10 | Sbi Biotech Co Ltd | ANTI-phospholipase D 4 ANTIBODY |
| SG10201800592SA (en) * | 2013-07-30 | 2018-03-28 | Sbi Biotech Co Ltd | Medicament comprising anti-phospholipase d4 antibody |
-
2014
- 2014-07-30 SG SG10201800592SA patent/SG10201800592SA/en unknown
- 2014-07-30 EP EP14761423.4A patent/EP3027656B1/en active Active
- 2014-07-30 MX MX2016001193A patent/MX381725B/es unknown
- 2014-07-30 SG SG11201600666SA patent/SG11201600666SA/en unknown
- 2014-07-30 CA CA2919736A patent/CA2919736C/en active Active
- 2014-07-30 HU HUE14761423 patent/HUE044469T2/hu unknown
- 2014-07-30 US US14/908,004 patent/US20160168266A1/en not_active Abandoned
- 2014-07-30 KR KR1020167002746A patent/KR102367760B1/ko active Active
- 2014-07-30 CN CN201480047721.6A patent/CN105745226B/zh active Active
- 2014-07-30 WO PCT/JP2014/070661 patent/WO2015016386A1/en not_active Ceased
- 2014-07-30 RU RU2016106708A patent/RU2709741C2/ru active
- 2014-07-30 TR TR2019/10330T patent/TR201910330T4/tr unknown
- 2014-07-30 JP JP2016503264A patent/JP6431523B2/ja active Active
- 2014-07-30 BR BR112016002001-4A patent/BR112016002001B1/pt active IP Right Grant
- 2014-07-30 PL PL14761423T patent/PL3027656T3/pl unknown
- 2014-07-30 ES ES14761423T patent/ES2736324T3/es active Active
- 2014-07-30 DK DK14761423.4T patent/DK3027656T3/da active
- 2014-07-30 AU AU2014297217A patent/AU2014297217B2/en active Active
-
2018
- 2018-11-01 JP JP2018206702A patent/JP2019014759A/ja not_active Ceased
-
2019
- 2019-09-25 JP JP2019173621A patent/JP6843449B2/ja active Active
-
2020
- 2020-12-18 US US17/127,202 patent/US20210130493A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015016386A1 (en) | 2015-02-05 |
| JP2016534022A (ja) | 2016-11-04 |
| AU2014297217B2 (en) | 2020-01-16 |
| MX381725B (es) | 2025-03-13 |
| RU2016106708A3 (es) | 2018-03-30 |
| US20160168266A1 (en) | 2016-06-16 |
| JP6843449B2 (ja) | 2021-03-17 |
| CA2919736C (en) | 2022-03-22 |
| CN105745226A (zh) | 2016-07-06 |
| CN105745226B (zh) | 2020-03-06 |
| JP2019214621A (ja) | 2019-12-19 |
| ES2736324T3 (es) | 2019-12-27 |
| BR112016002001A2 (pt) | 2017-08-29 |
| SG11201600666SA (en) | 2016-02-26 |
| KR20160034934A (ko) | 2016-03-30 |
| JP2019014759A (ja) | 2019-01-31 |
| CA2919736A1 (en) | 2015-02-05 |
| SG10201800592SA (en) | 2018-03-28 |
| BR112016002001B1 (pt) | 2023-04-25 |
| TR201910330T4 (tr) | 2019-07-22 |
| HUE044469T2 (hu) | 2019-10-28 |
| KR102367760B1 (ko) | 2022-02-24 |
| DK3027656T3 (da) | 2019-08-05 |
| EP3027656A1 (en) | 2016-06-08 |
| US20210130493A1 (en) | 2021-05-06 |
| RU2016106708A (ru) | 2017-09-01 |
| JP6431523B2 (ja) | 2018-11-28 |
| PL3027656T3 (pl) | 2019-10-31 |
| AU2014297217A1 (en) | 2016-02-18 |
| RU2709741C2 (ru) | 2019-12-19 |
| EP3027656B1 (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015000352A1 (es) | Métodos de tratamiento de una tauopatía | |
| IL272304A (en) | Bcma monoclonal antibody-drug conjugate | |
| DOP2017000031A (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso | |
| ECSP18005520A (es) | Anticuerpos de factor xi y métodos de uso | |
| MX2016001193A (es) | Medicamento que comprende anticuerpo anti-fosfolipasa d4. | |
| MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
| EA201691023A1 (ru) | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством | |
| TN2015000396A1 (en) | Antibody drug conjugates | |
| UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
| BR112016018891A2 (pt) | anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma | |
| MX2015012872A (es) | Anticuerpos anti-tau y metodos de uso. | |
| AR092662A1 (es) | Anticuerpos anti-ddr1 | |
| BR112014024494A2 (pt) | dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos | |
| BR112016025056A2 (pt) | uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica | |
| PH12015500480A1 (en) | Antibody formulations and uses thereof | |
| UY35718A (es) | Anticuerpos anti-csf-1r: métodos de expresión de los mismos. | |
| BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| TR201819828T4 (tr) | Anti-fosfolipaz d4 antikoru. | |
| UY36262A (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| EP3823991A4 (en) | ANTI-PD-1 ANTIBODIES, DOSAGE FORMS AND USES THEREOF | |
| EP2957632A4 (en) | HUMANIZED ANTI-CDH3 ANTIBODY, MEDICAMENT CONJUGATE THEREOF AND USE THEREOF | |
| UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
| UY36261A (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
| BR112015017981A2 (pt) | anticorpo humano específico para metapneumovírus humano, ou fragmento de ligação de antígeno do mesmo, seu uso e composição farmacêutica o compreendendo, bem como ácido nucleico isolado, vetor de expressão recombinante e célula hospedeira | |
| BR112015027388A2 (pt) | Anticorpo monoclonal ou porção do mesmo que se liga a cxcr5, seu método de produção e seu uso, polinucleotídeos, vetores de expressão, célula hospedeira, e composição farmacêutica |